Literature DB >> 9090715

A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans.

V Piotrovskij1, A Van Peer.   

Abstract

PURPOSE: To demonstrate the value of "first-pass" pharmacokinetic models (FPMs) in which the hepato-portal (HP) system is kinetically separated from the central compartment in fitting pharmacokinetic data obtained after intravenous (IV) and oral administration.
METHODS: Plasma concentration-time profiles of an investigational drug obtained in six healthy subjects each received 4 mg as an intravenous (IV) bolus dose and 10 mg as an oral solution served as a real data example. The common three- and four-compartment models with the first-order absorption and lag time (3CM and 4CM, respectively) in which HP system is assumed to be part of the central compartment were used as alternative models. We tested also: (i) the sensitivity of the output of FPM to variations in its parameters assuming IV and oral administration; (ii) practical estimability of the FPM parameters by fitting it to 20 simulated noisy data sets; (iii) distinguishability of FPM, 3CM and 4CM by fitting them to the simulated data sets.
RESULTS: FPM was shown to give the best fit as compared to 3CM or 4CM in 5 subjects of 6. The sensitivity of FPM was sufficient for the sake of parameter estimation. The "individual" means of parameter estimates obtained after fitting simulated data did not differ significantly from the preselected values. The variance in "individual" estimates was dependent on the sampling frequency. FPM was demonstrated to be distinguishable among relevant models.
CONCLUSIONS: FPM is preferable as compared to standard compartmental models for drugs extensively taken up by the intestine and/or the liver, and may have a broad spectrum of applications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090715     DOI: 10.1023/a:1012065130597

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  Comparative pharmacokinetics of coumarin anticoagulants. IV. Application of a three-compartmental model to the analysis of the dose-dependent kinetics of bishydroxycoumarin elimination.

Authors:  R Nagashima; G Levy; R A O'Reilly
Journal:  J Pharm Sci       Date:  1968-11       Impact factor: 3.534

2.  Clearance concepts in pharmacokinetics.

Authors:  M Rowland; L Z Benet; G G Graham
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

3.  Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve.

Authors:  M Gibaldi; S Feldman
Journal:  J Pharm Sci       Date:  1969-12       Impact factor: 3.534

4.  Influence of first-pass effect on availability of drugs on oral administration.

Authors:  M Gibaldi; R N Boyes; S Feldman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

5.  Optimal design of multioutput sampling schedules--software and applications to endocrine-metabolic and pharmacokinetic models.

Authors:  C Cobelli; A Ruggeri; J J Distefano; E M Landaw
Journal:  IEEE Trans Biomed Eng       Date:  1985-04       Impact factor: 4.538

6.  Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

7.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

8.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

9.  Serum and urine kinetics of rosaprostol in volunteers.

Authors:  G Segre; A I Fiaschi; E Bianchi; D Ciani; S Tedeschi
Journal:  Arzneimittelforschung       Date:  1988-12

10.  A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.

Authors:  D Smith; W Aldrich; M Dey; R Enever; R Warner; R Weierstall
Journal:  Drug Metab Dispos       Date:  1990 Jul-Aug       Impact factor: 3.922

View more
  4 in total

1.  Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Authors:  Sophie Peigné; François Bouzom; Karl Brendel; Charlotte Gesson; Sylvain Fouliard; Marylore Chenel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-12       Impact factor: 2.745

2.  Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

Authors:  A A Moghadamnia; A Rostami-Hodjegan; R Abdul-Manap; C E Wright; A H Morice; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

3.  Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women.

Authors:  Matthew L Zierhut; Marc R Gastonguay; Steven W Martin; Paolo Vicini; Pirow J Bekker; Donna Holloway; Philip T Leese; Mark C Peterson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-07-17       Impact factor: 2.745

4.  Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression.

Authors:  Carlos Perez-Ruixo; Stefaan Rossenu; Peter Zannikos; Partha Nandy; Jaskaran Singh; Wayne C Drevets; Juan Jose Perez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2020-10-31       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.